Online inquiry

IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ9806MR)

This product GTTS-WQ9806MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets BTLA gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric
RefSeq NM_001085357.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 151888
UniProt ID Q7Z6A9
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-BTLA, JS004(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ9806MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14167MR IVTScrip™ mRNA-Anti-IL6R, aIL6R88(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA aIL6R88
GTTS-WQ11504MR IVTScrip™ mRNA-Anti-MET, MetMAb(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MetMAb
GTTS-WQ7380MR IVTScrip™ mRNA-Anti-MS4A1, GA101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA GA101
GTTS-WQ13700MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ4338MR IVTScrip™ mRNA-Anti-IL5RA, BIW-8405(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BIW-8405
GTTS-WQ10379MR IVTScrip™ mRNA-Anti-TNFSF13B, LY2127399(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA LY2127399
GTTS-WQ1918MR IVTScrip™ mRNA-Anti-VEGFA, AGN 150998(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA AGN 150998
GTTS-WQ228MR IVTScrip™ mRNA-Anti-B4GALNT1, 14.18 mAb(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 14.18 mAb
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW